Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
about
A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group StudyFixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II studyLocally-advanced unresected uterine leiomyosarcoma with triple-modality treatment combining radiotherapy, chemotherapy and hyperthermia: A case report.Inhibition of uterine sarcoma cell growth through suppression of endogenous tyrosine kinase B signaling.Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line.Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015).New drugs and combinations for the treatment of soft-tissue sarcoma: a review.Recent progress in the diagnosis and treatment of ovarian cancerThe role of adjuvant therapy in uterine leiomyosarcomaPharmacological treatment for uterine leiomyosarcomas.Optimal management of uterine leiomyosarcoma.Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.
P2860
Q30370631-4EC5D72F-773E-4E88-A3FB-926E8CB5AA61Q30439459-DB63AE25-1FBD-41AD-BF71-5693E34946ADQ33343936-E4BB1984-3A94-4CD1-80E4-6F7EF1443524Q33379886-1A07541E-20B3-4A04-B59D-D80FDCEB4645Q33386535-D44CF1AD-2B0A-45AF-8EED-8102CDBF741AQ33844215-3411617B-E109-4BE9-A045-5FE7EA797399Q34387629-00967AA3-615C-4EA5-BB11-815F6E5E97EEQ36117059-C8505CF6-4CAA-43D3-BA2D-AFEFD36C734BQ36295510-1B936B24-6EB2-46BA-8255-D8001C454B0AQ36444369-D812FB24-C0F6-40B9-9B13-A54885223567Q36622857-4EEF108C-6F48-4C8D-ADE6-0C3A75FDE2EFQ36811788-85E45EB6-F6EC-4B31-8990-1181AEDDA6BCQ38270671-2C9D1AE1-60D5-427D-AE97-C9F6627AF4E8Q43173702-08ED3311-CFE8-4A36-87EC-3DB4F18DF276Q54711421-F9A1010F-0710-49DB-AF86-CA827A1C4B04
P2860
Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study.
description
1998 nî lūn-bûn
@nan
1998 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Prolonged oral etoposide in re ...... ecologic oncology group study.
@ast
Prolonged oral etoposide in re ...... ecologic oncology group study.
@en
type
label
Prolonged oral etoposide in re ...... ecologic oncology group study.
@ast
Prolonged oral etoposide in re ...... ecologic oncology group study.
@en
prefLabel
Prolonged oral etoposide in re ...... ecologic oncology group study.
@ast
Prolonged oral etoposide in re ...... ecologic oncology group study.
@en
P2093
P356
P1433
P1476
Prolonged oral etoposide in re ...... ecologic oncology group study.
@en
P2093
P304
P356
10.1006/GYNO.1998.5080
P407
P577
1998-08-01T00:00:00Z